BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 23447403)

  • 21. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
    Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
    Patterson SJ; Angus PW
    Curr Opin Organ Transplant; 2009 Jun; 14(3):225-30. PubMed ID: 19373086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
    Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
    Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
    Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
    Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation.
    Jiang L; Yan L; Wen T; Li B; Zhao J; Yang J; Xu M; Wang W
    Transplant Proc; 2013; 45(6):2326-30. PubMed ID: 23953544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
    Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
    Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.
    Angus PW; McCaughan GW; Gane EJ; Crawford DH; Harley H
    Liver Transpl; 2000 Jul; 6(4):429-33. PubMed ID: 10915163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis.
    Katz LH; Paul M; Guy DG; Tur-Kaspa R
    Transpl Infect Dis; 2010 Aug; 12(4):292-308. PubMed ID: 20002355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
    Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
    Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.
    Lee EC; Kim SH; Lee SD; Park H; Lee SA; Park SJ
    World J Gastroenterol; 2016 Apr; 22(14):3803-12. PubMed ID: 27076765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
    Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
    Lo CM; Liu CL; Lau GK; Chan SC; Ng IO; Fan ST
    Liver Transpl; 2005 Jul; 11(7):807-813. PubMed ID: 15973721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
    Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade.
    Neff GW; O'brien CB; Nery J; Shire N; Montalbano M; Ruiz P; Nery C; Safdar K; De Medina M; Tzakis AG; Schiff ER; Madariaga J
    Liver Transpl; 2004 Nov; 10(11):1372-8. PubMed ID: 15497163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
    Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.